189 GENERAL DISCUSSION REFERENCES 1. Staerk L, Wang B, Preis SR, Larson MG, Lubitz SA, Ellinor PT, et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: Cohort study based on longitudinal data from the Framingham Heart Study. BMJ (Online). 2018;361:k1453. 2. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BHC, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: The Rotterdam study. Eur Heart J. 2006;27(8):949–53. 3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 1991;22(8):983–8. 4. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373–498. 5. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythm control therapy in patients with atrial fibrillation. New England Journal of Medicine. 2020;383(14):1305–16. 6. Joosten LPT, Van Doorn S, Hoes AW, Nierman MC, Wiersma NM, Koek HL, et al. Safety of switching from Vitamin K antagonist to non-Vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: Rationale and design of the FRAIL-AF randomised controlled trial. BMJ Open. 2019;9(12):e032488. 7. Joosten LPT, van Doorn S, van de Ven PM, Köhlen BTG, Nierman MC, Koek HL, et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: Results of the FRAIL-AF randomized controlled trial. Circulation. 2024;149(4):279–89. 8. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Eng J Med. 2009;361(12):1139–51. 9. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Eng J Med. 2011;365(10):883–91. 10. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Eng J Med. 2011;365(11):981–92. 11. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Eng J Med. 2013;369(22):2093–104. 12. Joosten LPT, de Boer AR, van Eerde EJB, van Doorn S, Hoes AW, Bots ML, et al. Atrial fibrillation: Trends in prevalence and antithrombotic prescriptions in the community. Netherlands Heart Journal. 2022;30(10):459–65. 13. van den Dries CJ, van Doorn S, Rutten FH, Oudega R, van de Leur SJCM, Elvan A, et al. Integrated management of atrial fibrillation in primary care: Results of the ALL-IN cluster randomized trial. Eur Heart J. 2020;41(30):2836–44. 14. Steinberg B, Washam J. Appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. Trends in Cardiovasc Med. 2017;27(8):567–72. 15. Pokorney S, Peterson E, Piccini J. When less is not more. J Am Coll Cardiol. 2017;69(23):2791–3. 16. van Vugt S, Brouwer M, Verheugt F. Off-label use of non-vitamin K antagonist oral anticoagulants. J Am Coll Cardiol. 2017;69:2577–8. 17. Weitz J, Eikelboom J. Appropriate apixaban dosing: prescribers take note. JAMA Cardiol. 2016;1(6):635–6. 9
RkJQdWJsaXNoZXIy MTk4NDMw